Allakos Inc (ALLK) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allakos Inc (ALLK) has a cash flow conversion efficiency ratio of -0.511x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.36 Million) by net assets ($55.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Allakos Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Allakos Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Allakos Inc carry for a breakdown of total debt and financial obligations.
Allakos Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allakos Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bakrie Sumatera Plantations
JK:UNSP
|
-0.021x |
|
Ledlink Optics
TWO:5230
|
0.045x |
|
J.ESTINA Co.Ltd
KQ:026040
|
0.055x |
|
KPX Lifescience.Co.Ltd
KQ:114450
|
0.095x |
|
Nova MSC Bhd
KLSE:0026
|
-0.047x |
|
Numulae Gestion de Servicios SOCIMI SA
MC:YNUM
|
-0.001x |
|
Bioceres Crop Solutions Corp
NASDAQ:BIOX
|
0.038x |
|
Foxx Development Holdings Inc.
NASDAQ:FOXX
|
-0.024x |
Annual Cash Flow Conversion Efficiency for Allakos Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Allakos Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Allakos Inc market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $78.82 Million | $-93.62 Million | -1.188x | -72.16% |
| 2023-12-31 | $168.82 Million | $-116.48 Million | -0.690x | +23.49% |
| 2022-12-31 | $310.43 Million | $-279.97 Million | -0.902x | -93.29% |
| 2021-12-31 | $445.48 Million | $-207.85 Million | -0.467x | -168.01% |
| 2020-12-31 | $654.39 Million | $-113.92 Million | -0.174x | -36.96% |
| 2019-12-31 | $495.72 Million | $-63.01 Million | -0.127x | +39.17% |
| 2018-12-31 | $183.99 Million | $-38.45 Million | -0.209x | -154.42% |
| 2017-12-31 | $-58.77 Million | $-22.57 Million | 0.384x | -20.40% |
| 2016-12-31 | $-36.44 Million | $-17.58 Million | 0.482x | -- |
About Allakos Inc
As of May 15, 2025, operates as a subsidiary of Concentra Biosciences, LLC.